Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-871-2098
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$207.74 million
Profitability
Miscellaneous
Employees324
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions
What is Akebia Therapeutics' stock symbol?
Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."
How were Akebia Therapeutics' earnings last quarter?
Akebia Therapeutics Inc (NASDAQ:AKBA) issued its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.35) by $0.05. The biopharmaceutical company had revenue of $100.80 million for the quarter, compared to analyst estimates of $88.35 million. Akebia Therapeutics had a negative net margin of 75.64% and a negative return on equity of 36.92%. View Akebia Therapeutics' Earnings History.
When is Akebia Therapeutics' next earnings date?
What price target have analysts set for AKBA?
4 brokers have issued twelve-month price targets for Akebia Therapeutics' stock. Their predictions range from $9.00 to $17.00. On average, they anticipate Akebia Therapeutics' share price to reach $13.50 in the next twelve months. This suggests a possible upside of 182.4% from the stock's current price. View Analyst Price Targets for Akebia Therapeutics.
What is the consensus analysts' recommendation for Akebia Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akebia Therapeutics.
What are Wall Street analysts saying about Akebia Therapeutics stock?
Here are some recent quotes from research analysts about Akebia Therapeutics stock:
- 1. HC Wainwright analysts commented, "We continue to believe that positive outcomes, on both safety and efficacy, from all four studies is highly likely, and with data directly comparing its outcomes to the current standard of care in both DD and NDD patients, we continue to believe Akebia is well positioned for clinical, regulatory and commercial success. Affirm Buy. $17 PT. We employ a rNPV model, driven by U.S. sales of vadadustat (early 2022 launch, 75% POS, $2.5B peak U.S. sales) and Auryxia (peak sales of $409M in 2024) out to 2028 (zero terminal value) discounted at 12.5%. Risks to our investment thesis and target price include: (1) failure in pivotal Phase 3 vadadustat studies; (2) failure to secure regulatory approval of vadadustat; (3) a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing; and (4) intellectual property opposition." (9/9/2019)
- 2. According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (7/12/2019)
- 3. Mizuho analysts commented, "We expect Akebia to compete with two other products within next-generation (HIF-PHI) anemia drugs and we believe order of market entry will be; 1) Fibrogen (FGEN, Buy, $74 PT)’s roxadustat, 2) Akebia’s vadadustat, and 3) GlaxoSmithKline (GSK, Not-rated)’s daprodustat, which we think is ~ 6 months behind vadadustat." (12/4/2018)
Has Akebia Therapeutics been receiving favorable news coverage?
News articles about AKBA stock have been trending somewhat positive on Monday, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Akebia Therapeutics earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Akebia Therapeutics.
Who are some of Akebia Therapeutics' key competitors?
Some companies that are related to Akebia Therapeutics include Agios Pharmaceuticals (AGIO), Portola Pharmaceuticals (PTLA), Akcea Therapeutics (AKCA), Xencor (XNCR), Cambrex (CBM), Zai Lab (ZLAB), Ligand Pharmaceuticals (LGND), Nabriva Therapeutics (NBRV), Zogenix (ZGNX), Deciphera Pharmaceuticals (DCPH), Prestige Consumer Healthcare (PBH), Apellis Pharmaceuticals (APLS), Uniqure (QURE), Tricida (TCDA) and Insmed (INSM).
What other stocks do shareholders of Akebia Therapeutics own?
Who are Akebia Therapeutics' key executives?
Akebia Therapeutics' management team includes the folowing people:
- Mr. John P. Butler MBA, CEO, Pres & Director (Age 55)
- Mr. Jason A. Amello, Sr. VP, CFO & Treasurer (Age 51)
- Dr. Rita Jain, Sr. VP & Chief Medical Officer (Age 57)
- Ms. Nicole R. Hadas, SVP, Chief Legal Officer & Sec. (Age 46)
- Mr. Douglas Jermasek, VP of Marketing & Strategy
Who are Akebia Therapeutics' major shareholders?
Akebia Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.60%), Vanguard Group Inc. (4.35%), Nuveen Asset Management LLC (1.37%), Point72 Asset Management L.P. (1.37%), Rice Hall James & Associates LLC (1.27%) and Morgan Stanley (1.02%). Company insiders that own Akebia Therapeutics stock include Duane Nash and Michel Dahan. View Institutional Ownership Trends for Akebia Therapeutics.
Which major investors are selling Akebia Therapeutics stock?
AKBA stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Jacobs Levy Equity Management Inc., Morgan Stanley, Rice Hall James & Associates LLC, Artal Group S.A., Boston Partners, Prudential Financial Inc. and BNP Paribas Arbitrage SA. View Insider Buying and Selling for Akebia Therapeutics.
Which major investors are buying Akebia Therapeutics stock?
AKBA stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Nuveen Asset Management LLC, Point72 Asset Management L.P., Man Group plc, Sofinnova Investments Inc., DekaBank Deutsche Girozentrale, D. E. Shaw & Co. Inc. and Bank of New York Mellon Corp. View Insider Buying and Selling for Akebia Therapeutics.
How do I buy shares of Akebia Therapeutics?
Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Akebia Therapeutics' stock price today?
One share of AKBA stock can currently be purchased for approximately $4.78.
How big of a company is Akebia Therapeutics?
Akebia Therapeutics has a market capitalization of $568.17 million and generates $207.74 million in revenue each year. The biopharmaceutical company earns $-143,590,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Akebia Therapeutics employs 324 workers across the globe.View Additional Information About Akebia Therapeutics.
What is Akebia Therapeutics' official website?
How can I contact Akebia Therapeutics?
Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]
MarketBeat Community Rating for Akebia Therapeutics (NASDAQ AKBA)
MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Vote "Outperform" if you believe AKBA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKBA will underperform the S&P 500 over the long term. You may vote once every thirty days.
